

International Journal of Medical Sciences

2021; 18(6): 1348-1355. doi: 10.7150/ijms.52181

Research Paper

Association of Polymorphism rs1045411 in the HMGB1 Gene with Cancer Risk: Evidence from a Meta-analysis

Quansong Xia¹, Pengzuo Tao¹, Juan Xu²

1. Department of Clinical Laboratory, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.

2. Department of Internal Medicine, The People's Hospital of Guandu District, Kunming 650200, China.

🖂 Corresponding author: Juan Xu, Department of Internal Medicine, The People's Hospital of Guandu District, 63# Yinfeng Road, Kunming 650200, China. E-mail: kmxujuan@163.com

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.08.19; Accepted: 2021.01.04; Published: 2021.01.21

Abstract

The high-mobility group box protein 1 (HMGB1) rs1045411 polymorphism has been demonstrated to be associated with cancer risk in some studies. However, the results regarding this topic are inconsistent. A meta-analysis was applied to elucidate the association between the HMGB1 rs1045411 polymorphism and cancer risk. Ten relevant studies were subjected to our analysis, and pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. In total, of 3,918 cases and 5,296 controls were included in this study. The pooled ORs were calculated using a random-effects or fixed-effects model according to the heterogeneity. The pooled results revealed that TT genotype was significantly related to increased cancer risk in the comparisons of TT vs. CC+TC (OR=1.35; 95% CI: 1.09-1.67; p=0.005). Though no statistical significance was achieved between HMGB1 rs1045411 polymorphism and cancer risk in other four genetic models (T vs. C: OR=1.08, 95% CI 0.90-1.30; TC vs. CC: OR=1.01, 95% CI 0.82-1.24; CC vs. TC+TT: OR=0.95, 95% CI 0.77-1.18; TT vs. CC: OR=1.42; 95% CI 0.98-2.05), a trend of increased risk could be drawn. In the subgroup analysis by type of malignancy and ethnicity, no obvious difference was found in the tumour risk regarding the HMGB1 rs1045411 polymorphism amongst the cancer types except for breast cancer (OR=1.94; 95% CI: 1.05-3.59; p=0.03) and hepatocellular carcinoma (OR=1.82; 95% CI: 1.15-2.88; p=0.01), while rs1045411 polymorphism was positively associated with risks of cancer amongst Hans (OR=1.37; 95% CI: 1.11-1.69; p=0.004) rather than Caucasians (OR=0.89; 95% CI: 0.26-3.02; p=0.01). These results suggest that the HMGB1 rs1045411 polymorphism might be associated with increased cancer risk.

Key words: HMGB1, polymorphisms, meta-analysis

Introduction

Cancer is the most frequently diagnosed disease in the world, and the exact mechanisms of which remain unclear [1, 2]. Most studies have demonstrated that multiple genetic and epigenetic changes are involved in cancer development [3]. Therefore, studying the genetic and molecular mechanisms of cancer can help reveal the development process and predict the risk of cancer [1, 4]. Previously, reports have indicated that genetic variation plays an important role in cancer susceptibility and development. By genotyping single-nucleotide polymorphisms (SNPs), the distribution frequency of SNPs among cases and controls can be compared [5, 6]. Some reports have shown an association between

the SNPs rs1045411 and cancer risk; however, the results are controversial [7, 8].

As a highly conserved nuclear protein, HMGB1 functions as a chromatin structural protein in the nucleus or pro-inflammatory cytokine extracellularly [9, 10]. As a non-histone DNA-binding protein, nuclear HMGB1 promotes the assembly of site-specific DNA targets [11]. By contrast, extracellular HMGB1 acts as a damage-associated molecular pattern that serves as a key ingredient in many diseases such as inflammatory diseases and tumors [12]. Previously, we also reported that elevated HMGB1 levels are associated with lung cancer [9]. Additionally, accumulating evidences

suggests that high HMGB1 expression is closely related to the development and progression of cancer through its important functions in promoting proliferation, invasion and migration [13-15]. However, little is known regarding the effects of HMGB1 gene variants on cancer.

As HMGB1 rs1045411 polymorphism is closely correlated with altered binding of miR-505-5P in the 3'-UTR of mRNA transcripts, HMGB1 gene polymorphisms could emerge as a crucial player in cancer development through a post-transcriptional Chromosomal mechanism [7]. instability is considered important in the pathogenesis of cancer, and the HMGB1 loss can reduce telomerase activity, decrease telomere length, and increase chromosomal instability [16-19]. Thus, understanding the molecular bases of HMGB1 might be important for exploring its precise role in cancer [7]. Until now, many case-control studies have been carried out to explore the relevance of the HMGB1 polymorphism rs1045411 to cancer. However, due to the limitations of study design, such as a small sample size and lower statistical power, these studies have reported inconsistent results [1, 12, 20-27]. A meta-analysis to summarise the inconsistent results from the relevant studies may provide evidence for the correlation between the HMGB1 rs1045411 polymorphism and cancer risk.

Methods

Literature search and data extraction

Articles published up to April 2020 from PubMed, Embase, Wanfang Data Knowledge Service China Platform and National Knowledge Infrastructure were searched using the terms HMGB1 polymorphisms, with no language restrictions. The studies included in this meta-analysis were original studies that reported odds ratios (ORs) with 95% confidence intervals (CIs) or provided useful data to calculate ORs and 95% CIs. In this meta-analysis, all studies were independently verified against the inclusion and exclusion criteria by two investigators. Useful information was extracted from each included study. Allele frequencies were calculated from the corresponding genotype distributions when they were not given (n T= n TT×2+nCT, n C= n CC×2+nCT). These processes were also carried out independently by two investigators (Xia and Tao).

Statistical analysis

Pooled ORs and 95% CIs were calculated for allele contrast model (T *vs.* C), heterozygote model (TC *vs.* CC), homozygote model (TT *vs.* CC), dominant model (TT *vs.* CC+TC) and recessive model

(CC *vs.* TC + TT) by using STATA (v. 16.0; STATACORP LP, College Station, TX, USA) and Review Manager Software (v.5.2; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark), respectively. Additionally, χ^2 -based *Q* statistics and l^2 metrics were used to assess the heterogeneity between studies. When l^2 <50%, a fixed-effects model was used to calculate the pooled OR; otherwise, a random-effects model was used.

Results

A database that included each paper's first author, country, sample size, genotyping method and other useable information was set up based on the information extracted from 10 relevant studies that met the inclusion criteria (Table 1). Our original search yielded a total of 88 articles related to our keywords. Figure 1 summarizes the selection process of this study. After titles, key words and abstracts were screened, 69 of these articles were excluded. The full texts of 19 articles were reviewed, and an additional 9 articles were excluded (with 8 articles excluded for not providing usable data and 1 article excluded due to the duplication of the same article in different languages); thus, 10 studies remained for further review. One study [24] whose distribution of genotype deviated from Hardy-Weinberg equilibrium (HWE) (p HWE < 0.05) in the control was also included in this study but was excluded from the sensitivity analysis.

In total, of 3,918 cases and 5,296 controls were included in this study. The pooled ORs were calculated using a random-effects or fixed-effects model in terms of heterogeneity (Table 2). The pooled results demonstrated that HMGB1 rs1045411 polymorphism emerge as a risk factor for cancer, as a significant association between increased cancer risk and TT genotype was indicated in the comparison of the TT vs. CC+TC genotype (OR=1.35; 95% CI: 1.09-1.67; p=0.005). The same result was also detected by excluding one study [24] deviated from HWE in the comparison of the TT vs. CC+TC genotype (OR=1.33; 95% CI: 1.07-1.66; p=0.01) (Figure 2B). For the T vs. C genotype (OR=1.08; 95% CI: 0.90-1.30; p=0.40; Figure 2A) or CC vs. TC+TT genotype (OR=0.95; 95% CI: 0.77-1.18; p=0.65; Figure 2C) or TT vs. CC genotype (OR=1.42; 95% CI: 0.98-2.05; p=0.06; Figure 2D) or TC vs. CC genotype (OR=1.01; 95% CI: 0.82-1.24; *p*=0.93; Figure 2E), no significant association was detected, although the pooled ORs did not reach statistical significance in these four genetic models, a trend of increased risk could be drawn (Table 2).





Figure 1. Flow diagram of the search and selection process in this study.



		Sample Size			<i>p</i> value for HWE in control	
Study	Country/Area	Case	Control	Genotyping method	rs1045411C >T	
G Supic 2015 ²⁰	Caucasian	93	100	Taqman	0.33786	
Bin Wang 2016 ²¹	China	324	695	Taqman	0.72217	
Liling Yue 2016 ²²	China	524	518	Ligase-PCR	0.15262	
Hsinhung Wu 2016 ²³	Taiwan	309	305	Taqman	0.96957	
Jianxin Wang 2016 ²⁴	China	240	480	PCR-RFLP	0.0167	
Weiwei Hu 2017 ¹	China	372	379	Taqman	0.26819	
Dan Wang 2017 ²⁵	China	540	540	Ligase-PCR	0.5826	
Chiaowen Lin 2017 ²⁶	China	772	1200	Taqman	0.45078	
Bifei Huang 2018 ²⁷	China	313	217	Taqman	0.87461	
Shengchun Hung 201812	Taiwan	431	862	Taqman	0.32333	

HWE, Hardy-Weinberg equilibrium

Table 2. Meta-analysis of the HMGB1 rs1045411 polymorphism and cancer risk

	Sample	Sample size		Random or fixed-e	Test of heterogeneity					
Polymorphism	Study	Case	Control		OR (95%CI)	Z	<i>p</i> value	χ ²	<i>p</i> value	I ²
T vs. C	Overall ^a	1726	1843	10	1.08(0.90,1.30)	0.85	0.40	48.58	0.00001	81%
T vs. C	In HWE ^b	1616	1623	9	1.10(0.90,1.35)	0.92	0.36	47.66	0.00001	83%
TT vs. CC+TC	Overall ^a	217	182	10	1.35(1.09,1.67)	2.81	0.005	17.6	0.04	49%
TT vs. CC+TC	In HWE ^b	203	164	9	1.33(1.07,1.66)	2.56	0.01	17.31	0.03	54%
CC vs. TC+TT	Overall ^a	2657	3002	10	0.95(0.77,1.18)	0.45	0.65	46.76	0.00001	81%
CC vs. TC+TT	In HWE ^b	2513	2734	9	0.93(0.73,1.17)	0.63	0.53	45	0.00001	82%
TT vs. CC	Overall ^a	217	182	10	1.42(0.98,2.05)	1.88	0.06	21.96	0.009	59%
TT vs.CC	In HWE ^b	203	164	9	1.42(0.94,2.15)	1.68	0.09	21.87	0.005	63%
TC vs. CC	Overall ^a	1293	1489	10	1.01(0.82,1.24)	0.09	0.93	39.02	0.00001	77%
TC vs. CC	In HWE ^b	1211	1295	9	1.04(0.83,1.30)	0.34	0.74	36.87	0.00001	78%

^a All of the studies. ^b Excluding the study deviated from Hardy-Weinberg equilibrium (HWE).

In the subgroup analysis by type of malignancy, no obvious difference was found in the tumour risk regarding the HMGB1 rs1045411 polymorphism amongst the cancer types (Colorectal cancer: OR=1.59; 95% CI: 0.78-3.25; p=0.20; Urothelial cell carcinoma : OR=1.33; 95% CI: 0.79-2.23; p=0.28; Lung cancer: OR=0.84; 95% CI: 0.28-2.54; p=0.76; Oral squamous cell carcinoma: OR=0.91; 95% CI: 0.62-1.34; p=0.64; Uterine cervical cancer: OR=1.72; 95% CI: 0.77-3.81; p=0.18) except for breast cancer (OR=1.94; 95% CI: 1.05-3.59; p=0.03) and hepatocellular carcinoma

(OR=1.82; 95% CI: 1.15-2.88; p=0.01) in the dominant model (Figure 3). Next, subgroup analysis of rs1045411 stratified by ethnic groups was also conducted and fixed-effects model was used in the dominant genetic model. Our results demonstrated that rs1045411 polymorphism was positively associated with risks of cancer amongst Hans (OR=1.37; 95% CI: 1.11-1.69; p=0.004) rather than Caucasians (OR=0.89; 95% CI: 0.26-3.02; p=0.85; Figure 4).

A Note: Subscale: The second sec	Study or Subgroup									
$\frac{\text{Subtractions}}{\text{Berrichards} 2016} \frac{\text{Subtractions}}{138 + 648 +$		Case		Contro	a		Odds Ratio	Odds Ratio		
$ \begin{array}{c} \text{Bitel humag 2016} & 136 & 628 & 69 & 434 & 95% \\ \text{Bitel humag 2016} & 136 & 628 & 603 & 1380 & 10.5\% \\ \text{Chancem Lin 2017} & 334 & 1644 & 643 & 2400 & 11.7\% \\ \text{State line humag 2016} & 146 & 618 & 111 & 610 & 10.5\% \\ \text{State line humag 2016} & 146 & 618 & 111 & 610 & 10.5\% \\ \text{State line humag 2016} & 146 & 618 & 111 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 111 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 111 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 111 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 113 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 113 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 113 & 610 & 10.5\% \\ \text{Hendman Wu 2016} & 146 & 618 & 611 & 610 & 00001, P = 81\% \\ \text{Hendman Wu 2016} & 146 & 7127 & 1653 \\ \text{Hendman Wu 2016} & 160 & 100 & 100 & 100 & 100 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 146 & 7127 & 1653 \\ \text{Hendman Wu 2016} & 160 & 100 & 100 & 100 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 1727 & 100 & 501 & 100 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 1727 & 100 & 501 & 100 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 172 & 500 & 620 & 100 & 500 & 423 & 100 & 500 & 433 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 172 & 500 & 620 & 100 & 500 & 433 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 172 & 500 & 620 & 100 & 500 & 433 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 172 & 500 & 620 & 100 & 500 & 500 & 433 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 172 & 500 & 620 & 100 & 500 & 500 & 100 & 100 & 100 & 100 \\ \text{Hendman Wu 2016} & 172 & 500 & 710 & 120 & 100 &$		Events	Total			Weight I		M-H, Random, 95% Cl		
$\frac{Bin Versig 2016}{Dan Versig 2017} 13 6 6 8 0 01 1390 10.5\% 0.76 [10.60, 0.57]}{1210 171 30, 216} 0.75 (10.00, 0.71) 121 123, 216 01 010 107\% 121 123, 216 01 010\% 123 121 0105 123 0100\% 123 122 010\% 124 010\% 123 123 010\% 123 00\% 123 $	Bifei Huang 2018									
$\frac{D_{0} V_{0} V_{0} 2017}{D_{0} V_{0} V_$		113			1390		0.76 [0.60, 0.97]			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
Heinform Yu 2016 146 618 111 610 100% 138 [105,18] Ling Yu 2016 140 144 1048 123 680 10.4% 128 088,163 heing hund hung 2018 44 172 148 08 21 148 103 10.4% 128 088,163 heing hund hung 2018 44 172 148 08 21 148 103 10.4% 128 088,163 heing hund hung 2018 44 172 148 08 21 148 103 10.4% 128 088,163 heing hund hung 2018 44 172 148 08 21 148 103 10.4% 128 088,163 heing hund hung 2018 147 21 148 103 10.4% 128 088,163 heing hund hung 2018 147 21 148 103 10.4% 128 088,163 heing hund hung 2018 147 21 148 128 112 148 103 10.4% 128 088,163 heing hund hund hund hund hund hund hund hund										
$\begin{aligned} \begin{array}{llllllllllllllllllllllllllllllllllll$										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$\frac{\text{Briengebun Hum 2018}}{\text{Harting 2018}} \frac{414}{1224} \frac{1724}{198} \frac{198}{98} \frac{92}{83} \frac{934}{85} \frac{934}{$										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
Call (05): (1) B34 936 100.0% 109 (0.90, 1.30) University Tart = 0.07; Chr = 45.8; df = 0.P - 0.0001); F = 81% 0.0001; T = 81% 0.0001; T = 81% Diversity Tart = 0.07; Chr = 45.8; df = 0.P - 0.0001; T = 81% 0.0001; T = 81% 0.0001; T = 81% Diversity Tart = 0.07; Chr = 45.8; df = 0.P - 0.0001; T = 81% 0.0001; T = 81% 0.0001; T = 0.0000; T = 0.0001; T = 0.0001; T = 0.0001; T = 0.0001; T = 0.0000; T = 0.0001; T = 0.0000; T = 0.0001; T = 0.0000;										
Total events Heterogeneity: Tau ² = 0.07, Ch ² = 4.060 probed: 1:108(0:80,1:30) pooled: 1:108(0:80,1:30) B Support Subarcour Found 1:108(0:80,1:30) Case Control Support 1:108(0:80,1:30) pooled: 1:30 Support 1:35(1:00,1:67) pooled: 1:33 Support 1:35(1:00,1:67) pooled: 1:33(1:07,1:68) C Support Subarcour Found 1:33(1:00,1:67) pooled: 1:33(1:00,1:67) Total events Total events										
Heierogeneits, Tau" = 0.07, Chin" = 4.85, dif = 6 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 81% Test for overall effect 2 = 0.8 (P < 0.0001); P = 41%; Test for overall effect 2 = 0.8 (P = 0.005); poclet11: 38(1.06, 1.67); pocled2: 1.33(1.07.1.68) Chaoven Lin 2017 Test for overall effect 2 = 0.01% Double 2 = 0.000; poclet1: 1.38(1.06, 1.67); pocled2: 1.33(1.07.1.68) Chaoven Lin 2017 Test for overall effect 2 = 0.01% Double 2 = 0.01%; P = 40%; Test for overall effect 2 = 0.01%; P = 40%; Test for overall effect 2 = 0.01%; P = 40%; Test for overall effect 2 = 0.01%; P = 0.000; poclet1: 1.38(1.06, 1.67); pocled2: 1.33(1.07.1.68) C Test for overall effect 2 = 0.01%; P = 0.000; poclet1: 1.38(1.06, 1.67); pocled2: 1.33(1.07.1.68) C Test for overall effect 2 = 0.01%; P = 0.000; poclet1: 0.8(0.77, 1.18); pocled2: 0.33(1.07.1.68); D Test for overall effect 2 = 0.46; P = 0.000; poclet1: 0.8(0.77, 1.18); pocled2: 0.33(1.72, 1.18); D D D D D D D D D D D D D	Total (95% CI)		8334	1	9346	100.0%	1.08 [0.90, 1.30]	*		
Test for overall effect Z = 0.85 (p = 0.40) pooled 11.08(0.90,1.30) pooled 21.10(0.90.1.35) B Subor Subtrace Eq. (2000) Constrained and the second sec										
Case Control Odds Ratio Odds Ratio MH / Reed, 55% Cl MH / Reed, 55% Cl Odds Ratio Display: Close Control Odds Ratio Display: Close Control Odds Ratio Odds Ratio Display: Close Control Odds Ratio Odds Ratio <t< td=""><td></td><td></td><td></td><td>= 9 (P <</td><td>0.0000</td><td>1); I² = 81</td><td>% —</td><td>05 07 1 15 2</td></t<>				= 9 (P <	0.0000	1); I ² = 81	% —	05 07 1 15 2		
$B \\ \frac{5}{5} \\ $										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	pooled1:1.08(0.90,1.30) pooled	2:1.10(0	0.90,1.3)					
$ \frac{\text{Sturk varg 2016}}{\text{Birl Hang 2016}} = \frac{23}{13} \frac{10}{31} \frac{10}{10} \frac{217}{13} \frac{234}{16} \frac{10}{16} \frac{17}{13} \frac{234}{16} \frac{10}{16} \frac{17}{13} \frac{234}{16} \frac{10}{16} \frac{11}{13} \frac{234}{16} \frac{10}{16} \frac{10}{16} \frac{11}{13} \frac{11}{16} \frac{11}{17} \frac{11}{16} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{13} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{13} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{15} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{15} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{15} \frac{11}{13} \frac{11}{17} \frac{11}{15} $	В									
$ \frac{\text{Sturk varg 2016}}{\text{Birl Hang 2016}} = \frac{23}{13} \frac{10}{31} \frac{10}{10} \frac{217}{13} \frac{234}{16} \frac{10}{16} \frac{17}{13} \frac{234}{16} \frac{10}{16} \frac{17}{13} \frac{234}{16} \frac{10}{16} \frac{11}{13} \frac{234}{16} \frac{10}{16} \frac{10}{16} \frac{11}{13} \frac{11}{16} \frac{11}{17} \frac{11}{16} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{13} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{13} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{15} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{15} \frac{11}{13} \frac{10}{16} \frac{11}{13} \frac{11}{17} \frac{11}{15} \frac{11}{13} \frac{11}{17} \frac{11}{15} $		Cas	e	Contr	ol		Odds Ratio	Odds Ratio		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Study or Subgroup					Weight				
Bin Yang 2016 12 324 31 665 12.6% 0.82 0.42, 163 Chiaowen Lu 2017 33 540 8 540 5.0% 4.33 11.98, 9.46 6 Supic 2015 5 93 6 100 3.65 No 981 0.63, 13.9 Hainhung Yu 2016 17 309 10 305 6.3% 1.72 (0.77, 3.81) Janani Yang 2016 13 524 2 5 518 3.3% 2.81 (0.92, 7.37) Weiwei Hu 2017 6 190 7 197 4.5% 0.84 (0.28, 2.54) Heterogeneity. Ch ^p = 17.60, df = 9 (P = 0.00), P = 49% Total events Test for versil effect 2 = 2.18 (= 0.005) pooled 11.35(1.09, 1.67) pooled 21.33(1.07, 1.66) C C C Subc or Suboroup Events Total Events Total Weight M-H. Random, 95% CI Bin Yang 2016 373 524 22 17 9 5% Bin Yang 2016 40 373 524 22 17 9 5% Dots (1.07, 1.61) Dots (1.08, 1.66) C C C C Case Control Dist of range 2016 203 31 112 21 7 9 5% 0.86 (0.50, 0.66) Janani Yang 2016 772 72 73 1000.1% 1.42 (0.08, 1.67) Dots (1.35(1.09, 1.67) pooled 21.33(1.07, 1.66) C C Subor or Suboroup Events Total Events Total Weight M-H. Random, 95% CI Bin Yang 2016 423 324 425 695 10.6% 1.40(1.06, 1.86) Chiaowen Lu 2017 349 540 405 540 10.8% 0.66 (0.34, 1.07) D (0.48, 0.86) 0.51, 0.61 Janani Yang 2016 420 28 690 10.1% 1.420 (0.16, 7.07) O Subor 2016 373 524 389 518 10.7% 0.82 (0.62, 1.08) Shengchun Hung 2018 309 204 305 9.9% 0.66 (0.50, 0.66) Janani Wang 2016 373 524 389 518 10.7% 0.52 (0.67, 1.18) D (0.48, 73 100.0% 0.59 (0.57, 1.18) D (0.48, 73 100.0% 0.59 (0.57, 1.18) D (0.48, 73 100.0% 0.59 (0.57, 1.18) D (0.48, 73 100.0% 0.59 (0.77, 1.18) D (0.48, 74 (0.27, 1.18) Doole 2.0 33(1.72, 1.77) D C E E Subor or Suboroup Events Total Weight M-H. Random, 95% CI Bin Yang 2016 12 2.25 31 456 11.2% 0.74 (0.37, 1.48) D (0.48, Ratio D (0.48,								· · · · · ·		
Chiaeven Lin 2017 39 772 66 1200 32.6% 0.91 [0.61, 1.37] 6 Suptiz 2015 5 93 6 100 3.6% 0.89 [0.28, 3.02] Hainhung Yuu 2016 11 324 5 5 18 3.3% 1.59 [0.78, 3.29] Ling Yue 2016 13 524 5 5 18 3.3% 2.51 [0.92, 7.32] Shengchun Hung 2018 55 862 21 4.31 17.4% 1.39 [0.79, 2.33] Weiwei Hu 2017 6 190 7 1182 Heterogeneity: Ch ⁺ = 17.60, df = 0 e. 0.04; F = 49% Total (95% C) 14167 4673 100.0% 1.35 [1.09, 1.67] Total events 217 182 Heterogeneity: Ch ⁺ = 17.60, df = 0 e. 0.04; F = 49% Test for overall effect 2.2.31 ($P = 0.005$) C Case Control Study of Subaroup Vertices Total Weight MH Random, 95% Cl Heterogeneity: Ch ⁺ = 17.60, df = 0 e. 0.04; F = 49% Test for overall effect 2.2.31 ($P = 0.005$) C Case Control Study of Subaroup Vertices Total Vertices Total Vertices Total ($P = 0.005$) C Handom, 95% Cl Heterogeneity: Ch ⁺ = 17.60, df = 0 e. 0.04; F = 49% Test for overall effect 2.2.31 ($P = 0.005$) C Case Control Study of Subaroup Vertices Total Vertices Total Vertices Total ($P = 0.005$) C Case Control Def Case Control Study of Subaroup Vertices Total Vertices Total Vertices Total ($P = 0.005$) C Case Control Def Def Case Control Def Case Control Def Def Case Control Def Case Control Def Case Control Def Def Ca				31	695					
Dan Wang 2017 6 Supic 2017 6 Supic 2015 5 S S S S S S S S S S S S S S S S S S S				66	1200					
Heinhung Wu 2016 Jarani Wang 2016 Jarani Kang Jarani Jarani Jar			540	8	540	5.0%		\rightarrow		
Janavi Wang 2016 Liling Yue 2016 Liling Yue 2016 Liling Yue 2016 Shengchun Hung 2018 255 862 21 431 17.4% 133 [0.79, 2.23] Wetwei Hu 2017 6 190 7 187 4.6% 0.84 [0.28, 2.54] Total (9% C) Total (9% C) Total (9% C) Total 9% C) To	G Supic 2015							• •		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$ \begin{array}{c} \text{Total (95% C)} & 4167 & 4673 & 100.0\% & 1.35 [1.09, 1.67] \\ \hline \text{Total events} & 217 & 102 \\ \text{Heterogenek}(C, Chi = 71.6, 0.01 & 90 (p = 0.01; p = 49\% \\ \hline \text{Total or ownall effect } Z = 2.81 (p = 0.005) \\ \text{pooled1:1.35(1.09, 1.67) pooled2:1.33(1.07, 1.66)} \end{array} \\ \hline \\$										
$ \begin{array}{c} \text{Total events} & 217 & 182 \\ Heterogenetic, Chi = 17.60, (d) = 6.9 (e) 0.00, (p) = 4.9\%, (d) = 7.60, (d$	vverwer Hu 2017	6	190	7	187	4.5%	0.84 [0.28, 2.54]			
$ \begin{array}{c} \text{Total events} & 217 & 182 \\ Heterogenetic, Chi = 17.60, (d) = 6.9 (e) 0.00, (p) = 4.9\%, (d) = 7.60, (d$	Total (95% CI)		4167		4673	100.0%	1 35 [1 09 1 67]	•		
Heterogeneity: Chi=17.60, df=9 (P=0.04); P=49% Testfor overall effect Z=231 (Sec 10, 167) pooled2:1.33(1.07, 1.66) C Study or Subaroup Events Total Vents Total Weight MH.Random, 95% CI Bffei Huang 2016 220 331 132 217 9.5%, 1.14 (D 80, 1.63) Bffei Huang 2016 220 334 425 695 10.6%, 1.40 (D 80, 1.63) Bffei Huang 2017 349 540 405 540 10.8%, 1.26 (D 80, 1.63) Chiaowen Lin 2017 309 204 305 9.9%, 0.68 (D 50, 0.98) Janoin Wang 2016 123 324 425 695 10.6%, 1.40 (D 80, 1.63) Janoin Wang 2016 123 324 425 695 10.6%, 0.68 (D 50, 0.98) Janoin Wang 2015 144 240 266 480 10.1%, 1.19 (D 87, 1.63) Janoin Wang 2016 1373 524 389 518 10.7%, 0.82 (D 62, 1.08) Weiwei Hu 2017 130 190 109 187 8.6%, 1.55 (I .02, 2.38) Total events 265 70 Cm ² 4673 100.0%, 0.95 (D.77, 1.18) Total events 265 70 Cm ² 4673 100.0%, 0.95 (D.77, 1.18) Total events 265 73 1456 11.2%, 0.74 (D 37, 1.64) Bin Wang 2016 123 322 31 10 142 10.1%, 1.52 (D 07, 3.29) Total events 265 73 1456 11.2%, 0.74 (D 37, 1.64) Bin Wang 2016 12 235 31 456 11.2%, 0.74 (D 37, 1.64) Dan Wang 2017 33 524 686 799 14.9%, 0.84 (D 56, 1.27) Dan Wang 2016 12 33 522 81 431 11.1%, 0.77 (D 0.37, 1.64) Bin Wang 2016 12 33 526 13 445 11.2%, 0.74 (D 37, 1.64) Bin Wang 2016 12 33 382 84 133 10.0%, 4.79 (2.18, 1.550) Odds Ratio MH.Random, 95% CI Bin Wang 2016 17 197 10 214 9.7%, 1.93 (D 86, 4.32) Janoin Wang 2016 17 197 10 214 9.7%, 1.93 (D 86, 4.32) Janoin Wang 2016 17 197 10 214 9.7%, 1.93 (D 86, 4.32) Janoin Wang 2016 17 197 10 214 9.7%, 1.93 (D 86, 4.32) Janoin Wang 2016 13 386 5 394 7.4%, 2.71 (D 96, 7.68) Heinhung 2018 13 386 5 394 7.4%, 2.71 (D 97, 7.68) Heterogeneity Tau ² = 0.19; Chi ² = 1.86, 67 e9 (P = 0.009); P = 59% Testfor overall effect Z = 1.80, 67 = 9 (P = 0.009); P = 59% Testfor overall effect Z = 1.80, 67 = 9 (P = 0.009); P = 59% Testfor overall effect Z = 1.80, 67 = 9 (P = 0.009); P = 59% Testfor overall effect Z = 1.80, 67 = 9 (P = 0.009); P = 59% Testfor overall effect Z = 1.80, 67 = 0.72 (D 8, 9.3%) 0.80 (0.55, 1.16) Bin Huang 2018 80 2		217	4107	192	4075	100.076	1.55 [1.05, 1.07]	-		
Test for overall effect Z = 2.81 (P = 0.05) pooled:1:3.5(1.09,1.67) pooled2:1.33(1.07,1.66) C C C C Case Control			(P = 0.0		9%		_			
Doubed:11:35(1.09,1.67) pooled:21:33(1.07,1.66) Case Control Odds Ratio Mudy or Subgroup Devents Total Weight MH.Random, 95% CI MH.Random				,,,, - +	0 10					
C Case Control Odds Ratio Odds Ratio Study or Subgroup Fvents Total Fvents Total Vents Total Sec 233 Total Sec Total Sec 233 Total Total Sec 233 Total Total Sec 233 Total Total Sec 233 Total Sec 233 Total Sec 233 Total Sec Total Sec Total Sec Total Sec Total Total Sec <td< td=""><td></td><td></td><td></td><td>07 1 66</td><td>6</td><td></td><td></td><td>Case Control</td></td<>				07 1 66	6			Case Control		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	poolou 1. 1.00(1.00, 1.01) poolouz			/					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	C									
Study or Subgroup Events Total Events Total Weinth M-H. Random, 95% CI M-H. Random, 95% CI Bifel Huang 2018 200 313 132 217 9.5% 1.14 [0.80, 1.63] Bin Wang 2016 223 324 425 695 10.6% 1.40 [1.06, 1.63] Dan Wang 2017 349 540 405 540 10.8% 0.51 [0.47, 0.70] O Supic 2015 48 93 64 10.8% 0.80 [0.50, 0.68] 10.14 Hsinhung W2016 144 240 228 480 10.1% 1.19 [0.87, 1.63] Uling Yue 2016 373 524 389 518 10.7% 0.82 [0.82, 1.08] Shengchun Hung 2018 03 862 283 431 11.1% 0.73 [0.62, 0.32] Total events 2657 3002 Heterogeneity, Tau" = 0.09; Chr# - 46.76, df = 9 (P < 0.00001); P = 81%	U	Cae		Contro			Odde Patio	Odde Patio		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Study or Subgroup					Weight				
Bin Wang 2016 223 324 425 685 10.6% 14.0(10.6):1.88] Chiaowen Lin 2017 507 772 723 1200 11.8% 1.26(1.05;1.88] Dan Wang 2017 507 772 723 1200 11.8% 1.26(1.05;1.88] Subje 2015 48 93 64 100 6.7% 0.68(10.47, 0.79) G Supic 2016 144 240 268 480 10.1% 1.19(0.87, 1.63) Lilling Yue 2016 133 862 283 431 11.1% 0.73 [0.58, 0.33] Weiwei Hu 2017 130 190 199 187 8.6% 1.55(1.02, 2.36) Total events 2657 3002 Heterogeneity: Tau" = 0.09; ChP = 46.76, df = 9 (P < 0.00001); P = 81% Test for overall effect Z = 0.45 (P = 0.65) pooled 1:0.95(0.77, 1.18) pooled2:0.93(0.73, 1.17) D Case Control Study or Subgroup Events Total Events Total Weight MH.Random, 95% Cl Hienghuang 2016 12 235 31 466 66 789 14.9% 0.74 (0.37, 1.63) Bin Wang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.64) D Case Control Study or Subgroup Events Total Events Total Weight MH.Random, 95% Cl Hienghuang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.64) D Case Control Study or Subgroup Events Total Events Total Weight MH.Random, 95% Cl Hienghuang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.64) D Case Control Subgroup Events Total Events Total Weight MH.Random, 95% Cl Bifel Huang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.64) D Case Control Odds Ratio Study or Subgroup Events Total Events Total Weight MH.Random, 95% Cl Hienghuang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.64) D Case Control D Case Control										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Dan Wang 2017	349	540	405	540	10.8%	0.61 [0.47, 0.79]			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	G Supic 2015	48	93	64	100	6.7%	0.60 [0.34, 1.07]			
Liling Yue 2016 373 524 389 518 10.7% 0.82 [0.62, 1.08] Shengchun Hung 2018 503 862 283 431 11.1% 0.73 [0.58, 0.93] Weiwei Hu 2017 130 190 109 187 8.6% Total events 2657 3002 Heterogeneity: Tau ² = 0.09, Ch ² = 46.76, df = 9 ($P < 0.00001$); $P = 81\%$ Total events 2657 3002 Heterogeneity: Tau ² = 0.09, Ch ² = 46.76, df = 9 ($P < 0.00001$); $P = 81\%$ Test for overall effect Z = 0.45 ($P = 0.65$) pooled1:0.95(0.77, 1.18) pooled2:0.93(0.73, 1.17) D Study or Subgroup Events Total Events Total Weight M.H.Random, 95% CI Bifel Huang 2018 23 223 10 142 10.1% 1.52 [0.70, 3.29] Bin Wang 2016 12 235 31 456 11.2% 0.74 [0.37, 1.46] Chiaowen Lin 2017 33 382 8 413 10.0% 4.79 [2.18, 10.50] Hishnung Wu 2016 17 197 10 214 9.7% 1.93 [0.86, 4.32] Jaraki Mwang 2016 14 158 18 266 10.7% 1.45 [0.70, 3.09] Hishnung Wu 2016 17 197 10 214 9.7% 1.93 [0.86, 4.32] Jaraki Mwang 2016 14 158 18 266 10.7% 1.45 [0.70, 3.09] Hishnung Wu 2016 17 197 10 214 9.7% 1.93 [0.86, 4.32] Jaraki Mwang 2016 14 158 18 266 10.7% 1.45 [0.70, 3.09] Weiwei Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.20] Total events 217 182 Heterogeneity: Tau ² = 0.19; Ch ² = 21.96, df = 9 ($P = 0.009$); $P = 59\%$ Test for overall effect Z = 1.38 ($P = 0.06$) pooled1:1.42 (0.98, 2.05) pooled2:1.42 (0.94.2.15) E E Study or Subgroup Events Total Events Total Weight M.H.Random, 95% CI Bifel Huang 2018 90 290 75 208 9.3% 0.08 [0.55, 1.16] Bird Wang 2016 89 312 239 664 10.7% 0.71 [0.53, 0.51] Determine the 2017 75 208 9.3% 0.08 [0.55, 1.16] Bird Huang 2018 90 290 75 208 9.3% 0.08 [0.55, 1.16] Bird Huang 2018 90 290 75 208 9.3% 0.08 [0.55, 1.16] Bird Huang 2018 90 290 75 208 9.3% 0.08 [0.55, 1.16] Bird Huang 2018 89 312 239 664 10.7% 0.71 [0.53, 0.55] Chalewen Lin 2017 226 733 411 1134 12.1% 0.78 [0.64, 0.95]								_		
Shengchun Hung 2018 603 862 283 431 11.1 % 0.73 [0.56, 0.93] Weiwei Hu 2017 130 190 109 187 8.6% 1.55 [1.02, 2.36] Total events 2657 3002 0.000% 0.95 [0.77, 1.18] Total events 2657 3002 0.0000(1); P= 81% Test for overall effect Z = 0.45 (P = 0.65) 0.00001); P= 81% 0.55 [0.77, 1.18] pooled1:0.95(0.77, 1.18) pooled2:0.93(0.73, 1.17) Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Events Total Velight M-H, Random, 95% CI Bifei Huang 2018 23 223 10 142 10.1% 1.52 [0.70, 3.29] Bin Wang 2016 12 225 31 456 11.2% 0.74 [0.37, 1.46] Dan Wang 2017 33 382 8 413 10.0% 4.79 [2.18, 10.50] Odds Ratio G Supic 2015 5 53 6 75.9% 1.11 [0.32, 3.86] 0.74 [0.37, 1.46] Jamkin Wang 2016 13 386 5 394 7.4% 2.71 [0.87, 6.8] 0.72 [0.23, 2.20]			240		480	10.1%	1 10 0 07 1 621			
Weiwei Hu 2017 130 100 107 101 100 107 101 101 101 101 0.05 0.05 0.07 1 1.5 2 Total (95% Cl) 4467 100 0.95 0.05 0.07 1 1.5 2 Total (95% Cl) 44673 100 0.95 0.00001); P = 81% Total (95% Cl) Case Control Odds Ratio Study or Subgroup Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Bifel Huang 2018 23 23 23 23 23 23 23 23 23 23 23 23 23 23 23 23 <th 2"2"3<="" <="" colspan="2" td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th>	<td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			524	389	518	10.7%	0.82 [0.62, 1.08]			
Total events 2657 3002 Heterogenethy: Tau ² = 0.09; Ch ² = 46.76, df = 9 ($P < 0.0001$); P = 81% Test for overall effect Z = 0.05; Ch ² = 46.76, df = 9 ($P < 0.0001$); P = 81% Test for overall effect Z = 0.05; Ch ² = 46.76, df = 9 ($P < 0.0001$); P = 81% Total events 217 18 Shengchun Hung 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) His Nang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.46] Chiaowen Lin 2017 33 382 8 413 10.0% 4.79 [2.18, 10.50] His Nang 2016 17 197 10 214 9.7% 1.93 [0.86, 4.32] Jiarxin Wang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 3 386 5 394 7.4% 2.71 [0.86, 7.68] Shengchun Hung 2018 55 558 21 304 13.4% 1.47 (0.87, 2.49] Welwei Hu 2017 6 136 7 116 6.8% 0.72 (0.23, 2.20) Total events 217 182 Heterogeneity: Tau ² = 0.19; Chi ² = 21.96, df = 9 ($P = 0.009$); P = 59% Test for overall effect Z = 1.88 ($P = 0.06$) pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) E E Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Case Control Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95%	Shengchun Hung 2018	503	524 862	389 283	518 431	10.7% 11.1%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93]			
Total events 2657 3002 Heterogenethy: Tau ² = 0.09; Ch ² = 46.76, df = 9 ($P < 0.0001$); P = 81% Test for overall effect Z = 0.05; Ch ² = 46.76, df = 9 ($P < 0.0001$); P = 81% Test for overall effect Z = 0.05; Ch ² = 46.76, df = 9 ($P < 0.0001$); P = 81% Total events 217 18 Shengchun Hung 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) His Nang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.46] Chiaowen Lin 2017 33 382 8 413 10.0% 4.79 [2.18, 10.50] His Nang 2016 17 197 10 214 9.7% 1.93 [0.86, 4.32] Jiarxin Wang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.09) His Nang 2016 14 3 386 5 394 7.4% 2.71 [0.86, 7.68] Shengchun Hung 2018 55 558 21 304 13.4% 1.47 (0.87, 2.49] Welwei Hu 2017 6 136 7 116 6.8% 0.72 (0.23, 2.20) Total events 217 182 Heterogeneity: Tau ² = 0.19; Chi ² = 21.96, df = 9 ($P = 0.009$); P = 59% Test for overall effect Z = 1.88 ($P = 0.06$) pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) E E Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Case Control Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95%	Shengchun Hung 2018	503	524 862	389 283	518 431	10.7% 11.1%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93]			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Shengchun Hung 2018 Weiwei Hu 2017	503	524 862 190	389 283 109	518 431 187	10.7% 11.1% 8.6%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36]			
Testfor overall effect $Z = 0.45$ (P = 0.65) pooled1:0.95(0.77,1.18) pooled2:0.93(0.73,1.17) D Case Control Odds Ratio Study or Subgroup Events Total Events Total Weight M.H.Random, 95% CI Bifel Huang 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) Events Total Events Total Veight M.H.Random, 95% CI D an Wang 2016 12 235 31 456 11.2% Or 40 (0.37, 1.46) Chiaowen Lin 2017 33 382 8 413 10.0% 4.79 (2.18, 10.50) O Subjc 2015 5 53 6 70 5.9% 1.11 (0.32, 3.86) Hishihung Wu 2016 17 197 10 214 9.7% 1.93 (0.86, 4.32) Jianxin Wang 2016 14 158 18 266 10.7% 1.45 (0.70, 3.00) Liling Yue 2016 13 386 5 394 7.4% 2.71 (0.87, 2.49) Weiwei Hu 2017 6 136 7 116 6.8% 0.72 (0.23, 2.20) Total events 217 182 Heterogeneity: Tau ² = 0.19; Chi ² = 21.96, df = 9 (P = 0.009); P = 59% Testfor overall effect $Z = 1.88$ (P = 0.06) pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) E E Study or Subgroup Events Total Events Total Weight M.H.Random, 95% CI Bifel Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Bin Wang 2018 93 312 239 664 10.7% 0.71 [0.53, 0.95] Chiaowen Lin 2017 226 733 411 1134 12.7% 0.78 [0.64, 0.36] H.H.Random, 95% CI	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI)	503 130	524 862 190	389 283 109	518 431 187	10.7% 11.1% 8.6%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36]	→ → →		
Case Control Odds Ratio Case Control Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI MH Random, 95% CI Bin Wang 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) Bin Wang 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) Difter Huang 2018 23 223 10 142 10.1% 0.74 (0.37, 1.46) Chice Control Odds Ratio Chice Control Odds Ratio Chice Control Odds Ratio MH Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH Random, 95% CI ME Consection of the section of t	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events	503 130 2657	524 862 190 4167	389 283 109 3002	518 431 187 4673	10.7% 11.1% 8.6% 100.0%	0.82 (0.62, 1.08) 0.73 (0.58, 0.93) 1.55 (1.02, 2.36) 0.95 (0.77, 1.18)			
D Case Control Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M.H. Random, 95% CI M.H. Random, 95% CI Bifel Huang 2018 23 223 10 142 10.1% 1.52 (D.70, 3.29) Bin Wang 2016 12 223 31 456 11.2% 0.74 (0.37, 1.46) Ohawang 2017 39 54.6 66 789 14.9% 0.84 (0.56, 1.27) Dan Wang 2016 17 137 382 8 413 10.0% 4.79 (2.18, 10.50) Jamain Wang 2016 17 197 10 214 9.7% 1.93 (0.86, 4.32) 4.49% Jamain Wang 2016 14 158 18 286 10.7% 1.45 (0.70, 3.00) 1.41 (0.37, 2.49) 4.49% 2.71 (0.96, 7.68) 4.47 (0.87, 2.49) 4.47 (0.87, 2.49) 4.47 (0.87, 2.49) 4.47 (0.87, 2.49) 4.47 (0.87, 2.49) 4.45 (0.76, 2.20) 4.45 (0.76, 2.20) 4.45 (0.76, 2.20) 4.45 (0.76, 2.20) 4.45 (0.76, 7.68) 5.65 (0.7, 1.6, 1.5	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0	503 130 2657 19; Chi ² = 4	524 862 190 4167 6.76, df	389 283 109 3002	518 431 187 4673	10.7% 11.1% 8.6% 100.0%	0.82 (0.62, 1.08) 0.73 (0.58, 0.93) 1.55 (1.02, 2.36) 0.95 (0.77, 1.18)			
Case Control Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI Bifel Huang 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) Bin Wang 2016 12 235 31 456 11.2% 0.74 (0.37, 1.46) Ohawang 2017 39 546 66 789 14.9% 0.84 (0.56, 1.27) Dan Wang 2016 17 197 10 214 9.7% 1.93 (0.86, 4.32) Jamain Wang 2016 17 197 10 214 9.7% 1.93 (0.86, 4.32) Jamain Wang 2016 13 386 5 394 7.4% 2.71 (0.96, 7.68) Shengchun Hung 2018 55 558 21 304 13.4% 1.47 (0.87, 2.49) Weiwei Hu 2017 6 136 7 116 6.8% 0.72 (0.23, 2.20) Total (eys% CI) 2874 3184 100.0% 1.42 (0.98, 2.05)	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0.0 Test for overall effect: Z =	503 130 2657 9; Chi ² = 4 0.45 (P =	524 862 190 4167 6.76, df 0.65)	389 283 109 3002 f= 9 (P <	518 431 187 4673 0.0000	10.7% 11.1% 8.6% 100.0%	0.82 (0.62, 1.08) 0.73 (0.58, 0.93) 1.55 (1.02, 2.36) 0.95 (0.77, 1.18)			
Study or Subgroup Events Total Weight M.H. Random, 95% CI M.H. Random, 95% CI Bifel Huang 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) Image: Comparison of the compa	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = pooled 1:0.95(0.77, 1.18	503 130 2657 9; Chi ² = 4 0.45 (P =	524 862 190 4167 6.76, df 0.65)	389 283 109 3002 f= 9 (P <	518 431 187 4673 0.0000	10.7% 11.1% 8.6% 100.0%	0.82 (0.62, 1.08) 0.73 (0.58, 0.93) 1.55 (1.02, 2.36) 0.95 (0.77, 1.18)			
Bifei Huang 2018 23 223 10 142 10.1% 1.52 (0.70, 3.29) Bin Wang 2016 12 225 31 456 11.2% 0.74 (0.37, 1.46) Chiaowen Lin 2017 33 382 8 413 10.0% 4.79 (2.18, 10.50) O'S Supic 2015 5 53 6 70 5.9% 1.11 (0.32, 3.86) Hsinhung Wu 2016 17 197 10 214 9.7% 1.93 (0.86, 4.32) Jiarxin Wang 2016 14 158 18 286 10.7% 1.45 (0.70, 3.09) Liling Yue 2016 13 386 5 394 7.4% 2.71 (0.86, 7.68) Shengchun Hung 2018 55 558 21 304 13.4% 1.47 (0.87, 2.49) Weiwei Hu 2017 6 136 7 116 6.8% 0.72 (0.23, 2.20) Total (95% CI) 2874 3184 100.0% 1.42 (0.98, 2.05) Total (95% CI) 2874 3184 100.0% 1.42 (0.98, 2.05) pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) Case Control 0.5	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = pooled 1:0.95(0.77, 1.18	503 130 2657 9; Chi ² = 4 0.45 (P = 1) pooled2	524 862 190 4167 6.76, df 0.65) :0.93(0	389 283 109 3002 f= 9 (P <	518 431 187 4673 0.0000	10.7% 11.1% 8.6% 100.0%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] % –	Case Control		
Bin Wang 2016 12 235 31 456 11.2% 0.74 [0.37, 1.46] Chiaowen Lin 2017 39 546 66 789 14.9% 0.84 [0.56, 1.27] Dan Wang 2017 33 382 8 413 10.0% 4.78 [21,81.0.50] Osupic 2015 5 53 6 70 5.9% 1.11 [0.32, 3.86] Hsinhung Wu 2016 17 197 10 214 9.7% 1.45 [0.70, 3.00] Liling Yue 2016 13 386 5 394 7.4% 2.71 [0.86, 7.48] Janxin Wang 2017 6 136 7 145 [0.70, 3.00] 1.47 [0.87, 2.48] Liling Yue 2016 13 386 5 394 7.4% 2.71 [0.96, 7.48] Weiwei Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.20] Total (95% Cl) 2874 3184 100.0% 1.42 [0.98, 2.05] 0.5 0.7 1.5 2 rotal events 217 182 100.0% 1.42 [0.98, 2.05] 0.5 0.7 1.5 Case Control	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0.(Test for overall effect Z = pooled1:0.95(0.77,1.18 D	503 130 2657 19; Chi ² = 4 0.45 (P = 1) pooled2 Cas	524 862 190 4167 6.76, dt 0.65) :0.93(0 e	389 283 109 3002 f= 9 (P < .73,1.17 Conte	518 431 187 4673 0.0000	10.7% 11.1% 8.6% 100.0 %	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] % -	Case Control Odds Ratio		
Chiaowen Lin 2017 39 546 66 789 14.9% 0.84 [0.56, 1.27] Dan Wang 2017 33 382 8 413 10.0% 4.79 [2.18, 10.50] OS Supic 2015 5 53 6 70 5.9% 1.93 [0.36, 4.32] Jianxin Wang 2016 17 197 10 214 9.7% 1.93 [0.36, 4.32] Jianxin Wang 2016 14 158 18 286 10.7% 1.45 [0.70, 3.00] Ling Yue 2016 13 386 5 394 7.4% 2.71 [0.387, 7.68] Shengchun Hung 2018 55 558 21 304 13.4% 1.47 [0.87, 2.49] Weiwei Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.20] Total (95% CI) 2874 3184 100.0% 1.42 [0.98, 2.05] 1.5 Case Festor overall effect Z = 1.88 (P = 0.06) poold 1.42 [0.98, 2.05] 0.5 0.7 1.5 2 Case Control Odds Ratio Odds Ratio 0.48 [0.65, 1.16] M.H. Random, 95% CI Bifel Huang 2018 <	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup	503 130 2657 9; Chi ² = 4 0.45 (P = 1) pooled2 Cas <u>Events</u>	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u>	389 283 109 3002 f= 9 (P < .73,1.17 Conti Events	518 431 187 4673 0.0000) rol <u>Total</u>	10.7% 11.1% 8.6% 100.0 % 1); I ² = 81 <u>Weight</u>	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] % –	Case Control Odds Ratio		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% Cl) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D <u>Study or Subgroup</u> Bifei Huang 2018	503 130 2657 19; Chi ² = 4 0.45 (P = 1) pooled2 Cass <u>Events</u> 23	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u> 223	389 283 109 3002 f= 9 (P < .73,1.17 Conti <u>Events</u> 10	518 431 187 4673 0.0000) rol <u>Total</u> 142	10.7% 11.1% 8.6% 100.0% 1); I ² = 81 <u>Weight</u> 10.1%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] % - Odds Ratio <u>0.045 Ratio</u> <u>1.52 [0.70, 3.29]</u>	Case Control Odds Ratio		
G Supic 2015 5 53 6 70 5.9% 1.11 [0.32, 3.86] Hishung Wu 2016 17 197 10 214 9.7% 1.93 [0.36, 4.32] Janxin Wang 2016 14 158 18 286 10.7% 1.45 [0.70, 3.00] Liling Yue 2016 13 386 5 394 7.4% 2.71 [0.96, 7.68] Shengchun Hung 2018 55 558 21 304 13.4% 1.47 [0.87, 2.49] Weiwel Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.20] Total events 217 182 Heterogeneity: Tau" = 0.19; Chi" = 21.96, df = 9 (P = 0.009); P = 59% 1.42 [0.98, 2.05] 0.5 0.7 1.5 2 Total events 217 182 100.0% 1.42 [0.98, 2.05] 0.5 0.7 1.5 2 pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) E 0.5 0.7 1.5 2 Case Control Bife Huang 2018 90 290 75 208 9.3% 0.80	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifei Huang 2018 Bin Wang 2018	503 130 2657 9; Chi ² = 4 0.45 (P = 1) pooled2 Cas <u>Events</u> 23 12	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u> 223 235	389 283 109 3002 f= 9 (P < .73,1.17 Conti <u>Events</u> 10 31	518 431 187 4673 0.0000) rol <u>Total</u> 142 456	10.7% 11.1% 8.6% 100.0% 1); ² = 81 <u>Weight</u> 10.1% 11.2%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Hsinhung Wu 2016 Jiaratin Wang 2016 17 197 10 214 9.7% Jaratin Wang 2016 14 158 18 286 10.7% 1.45 (0.70, 3.00) Jiaratin Wang 2016 Shengchun Hung 2018 55 558 21 304 13.4% Veiwei Hu 2017 13 36 5 394 7.4% 2.71 (0.87, 2.49) Weiwei Hu 2017 13 36 5 394 7.4% 0.72 (0.23, 2.20) Total events 217 182 Test for overall effect Z = 1.88 (P = 0.06) pooled 1:1.42(0.98, 2.05) pooled 2:1.42(0.94, 2.15) E Case Control Study or Subgroup Events Total Events Total Events	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017	503 130 2657 19; Chi ² = 4 0.45 (P = 1) pooled2 Cass <u>Events</u> 23 12 39	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u> 223 235 546	389 283 109 3002 (= 9 (P < .73,1.17 <u>Contt</u> <u>Events</u> 10 31 66	518 431 187 4673 0.0000) rol <u>Total</u> 142 456 789	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 <u>Weight</u> 10.1% 11.2% 14.9%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Jiandri Wang 2016 14 158 18 286 10.7% 1.45 (0.70, 3.00) Liling Yue 2016 13 386 5 394 7.4% 2.71 (0.96, 7.68) Shengchun Hung 2018 55 558 21 304 13.4% 1.47 (0.87, 2.49) Weiwei Hu 2017 6 136 7 116 6.8% 0.72 (0.23, 2.20) Total (95% Cl) 2874 3184 100.0% 1.42 (0.98, 2.05) Total events 217 182 182 Heterogeneity: Tau ² = 0.19; Ch ² = 21.96, df = 9 (P = 0.009); P = 59% 0.5 0.7 1.5 2 Test for overail effect 2: 1.88 (P = 0.06) pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) 0dds Ratio 0dds Ratio E Case Control Odds Ratio 0dds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Bird Huang 2018 89 312 239 664 0.77 (10.53, 0.65) Chiaowen Lin 2017 226 733 411 1134 0.78 (0.8	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0.0 Test for overall effect Z = pooled1:0.95(0.777,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017	503 130 2657 9; Chi ² = 4 0.45 (P = 0) pooled2 0 pooled2 23 12 39 33	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u> 223 235 546 382	389 283 109 3002 f= 9 (P < .73,1.17 Conti <u>Events</u> 31 66 8	518 431 187 4673 0.0000) rol 142 456 789 413	10.7% 11.1% 8.6% 100.0% 1); ² = 81 <u>Weightt</u> 10.1% 11.2% 14.9% 10.0%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Liling Yue 2016 13 386 5 394 7.4% 2.71 [0.96, 7.68] Shengchun Hung 2018 55 558 21 304 13.4% 1.47 [0.87, 2.48] Weiwel Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.20] Total events 217 182 Heterogeneity: Tau ² = 0.19; Chi ² = 21.96, df = 9 (P = 0.009); I ² = 59% Test for overall effect Z = 1.88 (P = 0.06) pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) E Case Control Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Bifel Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Bin Wang 2016 89 312 239 664 10.7% 0.71 [0.53, 0.95] Chiaowen Lin 2017 226 733 411 1134 12.1% 0.78 [0.64, 0.96]	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifei Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 6 Supic 2015	503 130 2657 19; Chi [#] = 4 0.45 (P =) pooled2 Cass <u>Events</u> 23 12 39 33 33 5	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u> 223 235 546 382 53	389 283 109 3002 f= 9 (P < .73,1.17 Conti Events 10 31 66 8 8 6	518 431 187 4673 0.0000) rol 142 456 789 413 70	10.7% 11.1% 8.6% 100.0% 1); ² = 81 <u>Weightt</u> 10.1% 11.2% 14.9% 10.0% 5.9%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Shengchun Hung 2018 55 558 21 304 13.4% 1.47 [0.87, 2.49] Weiwei Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.0] Total (95% Cl) 2874 3184 100.0% 1.42 [0.98, 2.05] Total (95% Cl) 2874 3184 100.0% 1.42 [0.98, 2.05] Total events 217 182 0.00); I* = 59% Test for overall effect Z = 1.88 (P = 0.06) pooled 21.42 (0.98, 2.05) pooled 21.42 (0.94, 2.15) 0.5 0.7 1 1.5 2 Case Control Odds Ratio Odds Ratio Odds Ratio 0.80 [0.55, 1.16] H.Random, 95% Cl M.H.Random, 95% Cl Bird Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] 4 Bird Wang 2018 89 312 239 664 10.7% 0.71 [0.53, 0.95] 4 Chiaowen Lin 2017 226 733 411 1134 12.1% 0.78 [0.64, 0.95] 4	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect. Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hsinhung Wu 2016	503 130 2657 19; Chi ² = 4 0.45 (P =) pooled2 Cass Events 23 12 39 33 5 17	524 862 190 4167 6.76, df 0.65) :0.93(0 e <u>Total</u> 223 235 546 382 53 197	389 283 109 3002 f= 9 (P < .73,1.17 Conto <u>Events</u> 10 31 66 8 6 10	518 431 187 4673 0.0000) rol 142 456 789 413 70 214	10.7% 11.1% 8.6% 100.0% 11); I² = 81 Weightt 10.1% 11.2% 14.9% 14.9% 5.9% 9.7%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Weiwei Hu 2017 6 136 7 116 6.8% 0.72 [0.23, 2.20] Total (95% Cl) 2874 3184 100.0% 1.42 [0.98, 2.05] Total events 217 182 Heterogeneity: Tau*= 0.19; Chi*= 21.96, df = 9 (P = 0.009); P = 59% 1.42 [0.98, 2.05] pooled1:1.42(0.98, 2.05) pooled2:1.42(0.94, 2.15) 0.5 0.7 1 1.5 2 Case Control Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Bin Wang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Image: Chi avenue Lin 2017 226 733 411 1134 12.7% 0.71 [0.53, 0.95] Image: Chi avenue Lin 2017 0.644 0.78 0.71 [0.54, 0.96] Image: Chi avenue Lin 2017 Case Control Odds Ratio	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2015 Hsinhung Wu 2016 Jianxin Wang 2016	503 130 2667 19; Chi ² = 4 0.45 (P =) pooled2 Cass <u>Events</u> 39 33 12 39 33 5 17 14	524 862 190 4167 6.76, dt 0.65) :0.93(0 e <u>Total</u> 223 235 546 382 53 197 158	389 283 109 3002 (= 9 (P < .73,1.17 Conti Events 10 31 66 8 6 10 18	518 431 187 4673 0.0000) rol <u>Total</u> 142 456 789 413 70 214 286	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 <u>Weight</u> 10.1% 11.2% 14.9% 10.0% 5.9% 9.7% 10.7%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Total events 217 182 Heterogeneity: Tau ² = 0.19; Ch ² = 21.96, df = 9 (P = 0.009); P = 59% 0.5 0.7 1.5 2 Testfor overall effect Z = 1.88 (P = 0.06) 0.5 0.7 1.5 2 pooled1:1.42(0.98,2.05) pooled2:1.42(0.94,2.15) 0.5 0.7 1.5 2 E Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Bifel Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Image: Challenge Market Big	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.777,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hsinhung Wu 2016 Jiamxin Wang 2018 Lilling Yue 2018	503 130 2657 19; Chi ² = 4 0.45 (P =) pooled2 Cass Events 23 12 39 33 33 5 17 14 13	524 862 190 4167 6.76, df 0.65) 0.93(0 e <u>Total</u> 235 546 382 53 197 158 58	389 283 109 3002 (= 9 (P < .73,1.17 Contt Events 10 31 66 8 6 10 18 5 21	518 431 187 4673 0.0000)) rol 142 456 789 413 70 214 286 394	10.7% 11.1% 8.6% 100.0% 1); I ² = 81 Weight 10.1% 11.2% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Total events 217 182 Heterogeneity: Tau ² = 0.19; Ch ² = 21.96, df = 9 (P = 0.009); P = 59% 0.5 0.7 1.5 2 Testfor overall effect Z = 1.88 (P = 0.06) 0.5 0.7 1.5 2 pooled1:1.42(0.98,2.05) pooled2:1.42(0.94,2.15) 0.5 0.7 1.5 2 E Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Bifel Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Image: Challenge Market Big	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.777,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hsinhung Wu 2016 Jiamxin Wang 2018 Lilling Yue 2018	503 130 2657 19; Chi ² = 4 0.45 (P = 1) pooled2 Cas <u>Events</u> 12 39 33 5 17 14 13 55	524 862 190 4167 6.76, df 0.65) 0.93(0 e <u>Total</u> 235 546 382 53 197 158 58	389 283 109 3002 (= 9 (P < .73,1.17 Contt Events 10 31 66 8 6 10 18 5 21	518 431 187 4673 0.0000) rol 142 456 789 413 700 214 286 394 304	10.7% 11.1% 8.6% 100.0% 1); I ² = 81 Weight 10.1% 11.2% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Heterogeneity: Tau* = 0.19; Chia* = 21.96, df = 9 (P = 0.009); P = 59% 	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Heterogeneity: Tau ^a = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hisinhung Wu 2016 Jianxin Wang 2016 Shengchun Hung 2018 Weiwei Hu 2017	503 130 2657 19; Chi ² = 4 0.45 (P = 1) pooled2 Cas <u>Events</u> 12 39 33 5 17 14 13 55	524 862 190 4167 6.76, dt 0.65) 0.93(0 e 2 23 235 546 382 53 197 158 386 558 136	389 283 109 3002 (= 9 (P < .73,1.17 Contt Events 10 31 66 8 6 10 18 5 21	518 431 187 4673 0.0000) Total 142 456 789 413 70 214 286 394 304 116	10.7% 11.1% 8.6% 100.0% 1); * = 81 Weight 10.1% 11.2% 14.9% 10.0% 5.9% 9.7% 10.7% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Test for overall effect: Z = 1.88 (P = 0.06) 0.5 0.7 1 1.5 2 Case Control Case Control Odds Ratio Odds Ratio </td <td>Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Test for overall effect Z = pooled1:0.95(0.777,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 Hsinhung Wu 2018 Liling Yue 2018 Eihengchun Hung 2018 Weiwei Hu 2017 Total (95% CI)</td> <td>503 130 2657 19; Chi² = 4 0.45 (P = 1) pooled2 (P = 1) pooled2 23 12 39 33 5 5 5 6 17 14 13 55 6</td> <td>524 862 190 4167 6.76, dt 0.65) 0.93(0 e 223 235 546 382 53 197 158 386 558 136</td> <td>389 283 109 3002 (= 9 (P < 73,1.17 Contt Events 10 31 66 8 6 10 18 5 21 7</td> <td>518 431 187 4673 0.0000) Total 142 456 789 413 70 214 286 394 304 116</td> <td>10.7% 11.1% 8.6% 100.0% 1); * = 81 Weight 10.1% 11.2% 14.9% 10.0% 5.9% 9.7% 10.7% 13.4% 6.8%</td> <td>0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %</td> <td>Case Control Odds Ratio</td>	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.777,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 Hsinhung Wu 2018 Liling Yue 2018 Eihengchun Hung 2018 Weiwei Hu 2017 Total (95% CI)	503 130 2657 19; Chi ² = 4 0.45 (P = 1) pooled2 (P = 1) pooled2 23 12 39 33 5 5 5 6 17 14 13 55 6	524 862 190 4167 6.76, dt 0.65) 0.93(0 e 2 23 235 546 382 53 197 158 386 558 136	389 283 109 3002 (= 9 (P < 73,1.17 Contt Events 10 31 66 8 6 10 18 5 21 7	518 431 187 4673 0.0000) Total 142 456 789 413 70 214 286 394 304 116	10.7% 11.1% 8.6% 100.0% 1); * = 81 Weight 10.1% 11.2% 14.9% 10.0% 5.9% 9.7% 10.7% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
Case Control Odds Ratio Odds Ratio Case Control Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Bifel Huang 2018 90 75 208 0.3% 0.80 [0.55, 1.16] Bin Wang 2016 89 312 239 664 10.7% 0.71 [0.53, 0.95] Chiaowen Lin 2017 226 733 411 134 1134 12.1% 0	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2016 Chiaowen Lin 2016 Jianxin Wang 2016 Lilling Yue 2016 Shengchun Hung 2018 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events	503 130 2657 9; Chi ² = 4 0.45 (P =) pooled2 Cass Events 23 12 39 33 5 5 177 14 13 55 6 217	524 862 190 4167 6.76, dtl 0.05) 0.03(0 e Total 223 235 546 382 53 197 158 386 558 136 2874	389 283 109 3002 f= 9 (P < .73,1.17 Contt Events 10 31 66 6 10 18 5 211 7 7 182	518 431 187 4673 0.0000) rol <u>Total</u> 456 789 413 700 214 286 394 304 116 3184	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 Weight 10.1% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio		
pooled1:1.42(0.98,2.05) pooled2:1.42(0.94,2.15) E Case Control Odds Ratio Odds Ratio Study or Subgroup Events Total Events Odds Ratio M.H. Random, 95% CI Bifei Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Image: Control of the contro	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hisinhung Wu 2016 Jianxin Wang 2016 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0.	503 130 2657 19; Chi² = 4 0.45 (P =)) pooled2 (Cas Events 23 12 39 33 5 17 14 13 55 6 217 19; Chi² =	524 862 190 4167 6.76, dtf 0.65) :0.93(0 e Total 223 53 546 382 235 546 382 235 546 382 235 546 382 235 546 382 235 546 2387 4 223 235 546 24 24 24 24 24 24 24 24 24 24 24 24 24	389 283 109 3002 f= 9 (P < .73,1.17 Contt Events 10 31 66 6 10 18 5 211 7 7 182	518 431 187 4673 0.0000) rol <u>Total</u> 456 789 413 700 214 286 394 304 116 3184	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 Weight 10.1% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control		
Case Control Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Meight M-H, Random, 95% CI M-H, Random, 95% CI Bifei Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Image: Control of the second seco	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overail effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2016 Chiaowen Lin 2017 Dan Wang 2015 Hsinhung Wu 2016 Liling Yue 2016 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0. Test for overail effect: Z =	503 130 2657 (9; Chi ² = 4 0.45 (P =)) pooled2)) pooled2 Cas <u>Events</u> 12 33 35 5 5 7 17 14 13 55 5 6 217 19; Chi ² = 1.88 (P =	524 862 190 4167 6.76, dtf 0.65) :0.93(0 e Total 223 546 382 235 546 382 313 197 158 386 558 136 2874 22874 21.96, (389 283 109 3002 (= 9 (P < Contt Events 100 31 66 8 8 8 6 10 118 5 21 7 7 182 21 7	518 431 187 4673 0.0000)) rol 142 456 7899 413 700 214 286 394 413 116 3184 = 0.005	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 Weight 10.1% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M-H, Random, 95% CI 		
Case Control Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Meight M-H, Random, 95% CI M-H, Random, 95% CI Bifei Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Image: Control of the second seco	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overail effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2016 Chiaowen Lin 2017 Dan Wang 2015 Hsinhung Wu 2016 Liling Yue 2016 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0. Test for overail effect: Z =	503 130 2657 (9; Chi ² = 4 0.45 (P =)) pooled2)) pooled2 Cas <u>Events</u> 12 33 35 5 5 7 17 14 13 55 5 6 217 19; Chi ² = 1.88 (P =	524 862 190 4167 6.76, dtf 0.65) :0.93(0 e Total 223 546 382 235 546 382 313 197 158 386 558 136 2874 22874 21.96, (389 283 109 3002 (= 9 (P < Contt Events 100 31 66 8 8 8 6 10 118 5 21 7 7 182 21 7	518 431 187 4673 0.0000)) rol 142 456 7899 413 700 214 286 394 413 116 3184 = 0.005	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 Weight 10.1% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M-H, Random, 95% CI 		
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Bifel Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] • Bin Wang 2016 89 312 239 664 10.7% 0.77 [0.53, 0.95] • Chiaowen Lin 2017 226 733 411 1134 12.1% 0.78 [0.64, 0.96] •	Shengchun Hung 2018 Weiwei Hu 2017 Total events Heterogeneity: Tau ^a = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifei Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hsinhung Wu 2016 Jiamxin Wang 2016 Liling Yue 2016 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0. Test for overall effect Z = pooled1:1.42(0.98,2.05)	503 130 2657 (9; Chi ² = 4 0.45 (P =)) pooled2)) pooled2 Cas <u>Events</u> 12 33 35 5 5 7 17 14 13 55 5 6 217 19; Chi ² = 1.88 (P =	524 862 190 4167 6.76, dtf 0.65) :0.93(0 e Total 223 546 382 235 546 382 313 197 158 386 558 136 2874 22874 21.96, (389 283 109 3002 (= 9 (P < Contt Events 100 31 66 8 8 8 6 10 118 5 21 7 7 182 21 7	518 431 187 4673 0.0000)) rol 142 456 7899 413 700 214 286 394 413 116 3184 = 0.005	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 Weight 10.1% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M-H, Random, 95% CI 		
Bifei Huang 2018 90 290 75 208 9.3% 0.80 [0.55, 1.16] Bin Wang 2016 89 312 239 664 10.7% 0.71 [0.53, 0.95] Chiaowen Lin 2017 226 733 411 1134 12.1% 0.78 [0.64, 0.96]	Shengchun Hung 2018 Weiwei Hu 2017 Total events Heterogeneity: Tau ^a = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifei Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hsinhung Wu 2016 Jiamxin Wang 2016 Liling Yue 2016 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0. Test for overall effect Z = pooled1:1.42(0.98,2.05)	503 130 2657 19; Chi ² = 4 0.45 (P = :) pooled2 Cas <u>Events</u> 12 39 33 55 6 217 14 13 55 6 217 19; Chi ² = 4 217 19; Chi ² = - 18; Chi ² = - 19; Chi ² = - 19; Chi ² = - 10; Ch	524 862 190 4167 6.76, dt 0.65) :0.93(0 e Total 223 235 546 382 538 235 546 382 538 197 158 386 558 386 558 2874 21.96, c 0.06) :1.42(0	389 283 109 3002 (= 9 (P < Contt <u>Events</u> 10 31 6 6 6 8 8 8 6 10 11 7 7 182 2 17 9 (P < 9 (P < 9 10 9 11 9 11 9 11 9 11 9 11 9 11 9 1	518 431 187 4673 0.0000) rol 142 456 789 413 70 214 286 394 3184 = 0.009)	10.7% 11.1% 8.6% 100.0% 11); I [≠] = 81 Weight 10.1% 14.9% 10.0% 5.9% 9.7% 10.7% 7.4% 13.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M.H. Random, 95% CI M.H. Random, 95% CI 0.5 0.7 1.5 2 Case Control		
Bin Wang 2016 89 312 239 664 10.7% 0.71 [0.53, 0.95]	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau® = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bifel Huang 2018 Chiaowen Lin 2017 Dan Wang 2015 Hsinhung Wu 2016 Jianxin Wang 2016 Shengchun Hung 2018 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau® = 0. Test for overall effect Z = pooled1:1.42(0.98,2.05)	503 130 2657 19; Chi ² = 4 0.45 (P =) pooled2 Cass Events. 217 14 13 55 6 217 19; Chi ² = 4 17 14 13 55 6 217 19; Chi ² = 4 217 19; Chi ² = 4 217 217 217 218 218 218 218 217 217 218 218 217 217 218 218 218 217 217 217 218 218 218 217 217 217 218 218 218 217 217 217 218 218 218 217 217 218 218 218 217 217 218 218 218 217 217 218 218 218 218 217 217 217 218 218 218 218 218 218 218 218	524 862 190 4167 6.76, dt 0.65) 0.093(0 e Total 223 53 235 546 382 53 197 158 386 558 136 558 136 2874 221, 96, (c 0.06) 1.142(0)	389 283 109 3002 (= 9 (P < Control Control 66 8 8 6 6 6 8 8 6 10 11 31 5 21 11 7 7 1822 (P < 9 (P < Control 9 (P < Control 19 (P < 19) (P < 19) (518 431 187 4673 0.0000) rol 142 456 789 413 70 214 2456 394 3142 3184 = 0.005) trol	10.7% 11.1% 8.6% 100.0% 11); ² = 81 10.1% 11.2% 14.9% 9.7% 10.0% 7.4% 10.7% 7.4% 10.7% 6.8% 100.0%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M.H. Random, 95% CI M.H. Random, 95% CI 0.5 0.7 1.5 2 Case Control Odds Ratio		
Chiaowen Lin 2017 226 733 411 1134 12.1% 0.78 [0.64, 0.96]	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifei Huang 2018 Chiaowen Lin 2017 Dan Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 G Supic 2015 Hsinhung Wu 2016 Jiamxin Wang 2018 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0. Test for overall effect Z = pooled1:1.42(0.98,2.05) E	503 130 2657 19; Chi ² = 4 0.45 (P = :) pooled2 Cass Events 23 12 39 33 55 17 14 13 55 6 217 19; Chi ² = : 1.82 (P = :) pooled2 217 19; Chi ² = : 1.82 (P = :) pooled2 217 19; Chi ² = : 10; Chi ² = : 11; Chi ² = : 10; Chi ² = : 11; Chi ² = : 10; Chi ² = : 10	524 862 190 4167 6.76, dfl 0.65) :0.93(0 e Total 223 235 546 382 546 382 548 137 158 386 558 137 158 386 558 136 2874 21.96, cf 0.06) :1.42(0 \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) \$20,000) :1.42(0) :1.42(0) \$20,000) :1.42(0) :1.42	389 283 109 3002 (= 9 (P < Contt Events 10 31 666 8 8 6 6 10 118 6 6 6 10 118 5 21 21 7 7 1822 21f = 9 (P <	518 431 187 4673 0.0000) rol 142 456 789 413 70 214 286 3142 314 304 116 3184 = 0.005) trol	10.7% 8.6% 11.1% 8.6% 100.0% 11); I [*] = 81 10.1% 10.7% 10.7% 6.8% 10.7% 6.8% 100.0% 10.7% 10.7% 10.7% 10.7% 10.4% 6.8%	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M.H. Random, 95% CI M.H. Random, 95% CI 0.5 0.7 1.5 2 Case Control Odds Ratio		
	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ² = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2017 Chai wang 2017 Hsinhung Wu 2018 Liling Yue 2018 Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity, Tau ² = 0. Test for overall effect Z = pooled1:1.42(0.98,2.05 E Study or Subgroup Bifel Huang 2018	503 130 2657 19; Chi ² = 4 0.45 (P =) pooled2 Cas Events 12 33 35 17 14 13 55 6 217 19; Chi ² = 1.88 (P =) pooled2 Cas Cas Cas Cas Cas Cas Cas Cas	524 862 190 4167 6.76, dt 0.0.93(0 e Total 223 536 546 382 538 136 558 136 558 136 2874 21.96, (0.06) :1.42(0 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	389 283 109 3002 (= 9 (P < Contt Events 10 31 31 6 8 8 8 6 6 8 8 8 6 10 11 7 7 9 (P = 9 (P = 9 (P < 2002) 11 9 11 9 11 9 11 9 11 9 11 9 11 9 11	518 431 187 4673 0.0000) rol 142 4566 789 413 700 214 286 394 394 304 116 3184 = 0.009) trol <u>trol</u>	10.7% 11.1% 8.6% 100.0% 10.1% 10.1% 10.1% 11.2% 10.1% 10.1% 11.2% 10.1% 5.9% 10.0% 5.9% 10.0% 5.9% 10.0% 1.1% 1.2% 1.1% 1.2% 1.1% 1.2% 1.1% 1.2% 1.1% 1.2% 1.1% 1.2% 1.1% 1.2% 1.1% 1.2	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M.H. Random, 95% CI M.H. Random, 95% CI Odds Ratio M.H. Random, 95% CI		
	Shengchun Hung 2018 Weiwei Hu 2017 Total (95% CI) Total events Heterogeneity: Tau ^a = 0.0 Test for overall effect Z = pooled1:0.95(0.77,1.18 D Study or Subgroup Bifel Huang 2018 Bin Wang 2018 Chiaowen Lin 2017 Dan Wang 2016 Chiaowen Lin 2017 Dan Wang 2016 Shengchun Hung 2018 Jianxin Wang 2016 Shengchun Hung 2018 Weiwei Hu 2017 Total events Heterogeneity: Tau ^a = 0. Test for overall effect Z = pooled1:1.42(0.98,2.05) E Study or Subgroup Bifei Huang 2018 Bin Wang 2018	503 130 2667 19; Chi ² = 4 0.45 (P =) pooled2 Cass Events. 12 33 12 33 55 17 14 13 55 6 217 19; Chi ² = 4 (Cass 23 33 55 6 217 19; Chi ² = 4 (Cass 12 39 33 55 6 217 19; Chi ² = 4 (Cass 12 39 33 55 6 217 19; Chi ² = 4 (Cass 12 39 33 55 6 217 19; Chi ² = 4 (Cass 12 39 33 55 6 217 19; Chi ² = 4 (Cass 12 39 33 55 6 217 14 13 55 6 217 19; Chi ² = 4 (Cass 17 14 13 55 6 217 19; Chi ² = 5 (Cass 17 14 13 55 6 217 19; Chi ² = 4 (Cass 217 19; Chi ² = 5 (Cass 217 19; Chi ² = 5 (Cass 217 14 217 19; Chi ² = 6 (Cass 217 19; Chi ² = 6 (Cass 217 19; Chi ² = 6 (Cass 218 (Cass 20) 200 200 200 200 200 200 200	524 862 139 4167 6.76, dt 0.65) :0.93(0 e Total 223 235 546 558 382 533 382 533 197 158 382 533 197 158 382 538 136 22874 21.96, c 0.06) :1.42(0 e 21.90, c 1.42(0 e 2.93, c 2.93, c 2.94, c 2	389 283 109 3002 = 9 (P < Control Control 8 6 6 8 8 6 6 8 8 6 6 8 8 6 10 11 31 31 6 6 8 8 7 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	518 431 187 4673 0.0000) rol 1422 456 789 413 70 214 286 789 214 286 394 3184 = 0.009) trol <u>Totas</u> 3184 = 0.009)	10.7% 11.1% 8.6% 100.0% 11); ² = 81 10.1% 11.2% 14.9% 10.1% 14.9% 10.7% 7.4% 10.7% 7.4% 10.7% 10	0.82 [0.62, 1.08] 0.73 [0.58, 0.93] 1.55 [1.02, 2.36] 0.95 [0.77, 1.18] %	Case Control Odds Ratio M.H. Random, 95% CI		

Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Bifei Huang 2018	90	290	75	208	9.3%	0.80 [0.55, 1.16]	
Bin Wang 2016	89	312	239	664	10.7%	0.71 [0.53, 0.95]	
Chiaowen Lin 2017	226	733	411	1134	12.1%	0.78 [0.64, 0.96]	
Dan Wang 2017	158	507	127	532	11.0%	1.44 [1.10, 1.90]	
G Supic 2015	40	88	30	94	6.3%	1.78 [0.97, 3.25]	
Hsinhung Wu 2016	112	292	91	295	9.9%	1.39 [0.99, 1.96]	
Jianxin Wang 2016	82	226	194	462	10.1%	0.79 [0.57, 1.09]	
Liling Yue 2016	138	511	124	513	10.9%	1.16 [0.88, 1.54]	
Shengchun Hung 2018	304	807	127	410	11.3%	1.35 [1.05, 1.73]	
Weiwei Hu 2017	54	184	71	180	8.4%	0.64 [0.41, 0.99]	
Total (95% CI)		3950		4492	100.0%	1.01 [0.82, 1.24]	+
Total events	1293		1489				
Heterogeneity: Tau ² = 0.08 Test for overall effect: Z = 0 pooled1:1.01(0.82,1.24) p	.09 (P =	0.93)			1); I² = 77	%	0.5 0.7 1 1.5 2 Case Control

Figure 2. Forest plot of the meta-analysis for the association of the HMGB1 rs1045411 allele distribution with cancer risk by comparing T vs. C under the random-effects model (A). TT vs. CC+TC under the fixed-effects model (B). CC vs. TC+TT under the random-effects model(C). TT vs. CC under the random-effects model (D). TC vs. CC under the random-effects model (E). (1) Including all of the 10 studies. (2) Excluding the study deviated from Hardy-Weinberg equilibrium. Abbreviations: CI, confidence interval; IV, inverse variance.

~	Experimen		Contr			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
2.1.1 Breast cancer							
Liling Yue 2016	13	524	5	518	3.3%	2.61 [0.92, 7.37]	
Bifei Huang 2018	23	313	10	217	7.3%	1.64 [0.77, 3.52]	
Subtotal (95% CI)		837		735	10.5%	1.94 [1.05, 3.59]	
Total events	36		15				
Heterogeneity: Chi ² = 0.			l ² = 0%				
Test for overall effect: Z :	= 2.12 (P = 0.0	33)					
2.1.2 Hepatocellular ca	rcinoma						
Dan Wang 2017	33	540	8	540	5.0%	4.33 [1.98, 9.46]	
Bin Wang 2016	12	324	31	695	12.6%	0.82 [0.42, 1.63]	
Subtotal (95% CI)		864	0.	1235	17.6%	1.82 [1.15, 2.88]	-
Total events	45		39	1200		102 [110, 2100]	
Heterogeneity: Chi ² = 9.1		0 002		*			
Test for overall effect: Z:			7,1 = 30				
2.1.3 Colorectal cancer Jianxin Wang 2016	14	240	18	480	7.5%	1.59 [0.78, 3.25]	
Subtotal (95% CI)	14	240	10	480	7.5%	1.59 [0.78, 3.25]	
Total events	14	240	18	400	1.570	1.55 [0.16, 5.25]	
Heterogeneity: Not appli			18				
Test for overall effect: Z:		202					
restion overall ellect. Z.	- 1.27 (F - 0.2	20)					
2.1.4 Urothelial cell car							
Shengchun Hung 2018	55	862	21	431	17.4%	1.33 [0.79, 2.23]	
Subtotal (95% CI)		862		431	17.4%	1.33 [0.79, 2.23]	-
Total events	55		21				
Heterogeneity: Not appli	icable						
Test for overall effect: Z :	= 1.08 (P = 0.2	28)					
2.1.5 Lung cancer							
Weiwei Hu 2017	6	190	7	187	4.5%	0.84 [0.28, 2.54]	
Subtotal (95% CI)		190		187	4.5%	0.84 [0.28, 2.54]	
Total events	6		7			• • • •	
Heterogeneity: Not appli	-						
Test for overall effect: Z :		76)					
	all carcinoma						
2.1.6 Oral squamous ce G Supic 2015	eli carcinoma 5	93	6	100	3.6%	0.89 [0.26, 3.02]	.
Chiaowen Lin 2017	39	772	-	1200	32.6%	0.91 [0.61, 1.37]	
Subtotal (95% CI)		865	00	1300	36.2%	0.91 [0.62, 1.34]	-
Total events	44		72				
Heterogeneity: Chi ² = 0.1		0.97)					
Test for overall effect: Z:			0,0				
471Horing conde-1-	-						
2.1.7 Uterine cervical c		000		005	0.00	4 70 10 77 0 011	
Hsinhung Wu 2016	17	309	10	305	6.3%	1.72 [0.77, 3.81]	
Subtotal (95% CI)		309		305	6.3%	1.72 [0.77, 3.81]	
Total events	17		10				
Heterogeneity: Not appli Test for overall effect: Z :		18)					
restion overall enect. Z.	- 1.55 (1 - 0.1	,					
Fotal (95% CI)		4167		4673	100.0%	1.35 [1.09, 1.67]	◆
Total events	217		182				
Heterogeneity: Chi ² = 17	7.60, df = 9 (P	= 0.04); I ² = 499	%			0.2 0.5 1 2 5
Test for overall effect: Z :	= 2.81 (P = 0.0	005)					Case Control
Test for subaroup differe	ences: Chi² =	8.18. 0	df = 6 (P =	= 0.23)	I ² = 26.7	%	Case Control

Figure 3. Forest plot of rs1045411 in HMGB1 gene and risk of cancer: subgroup analysis by cancer type using the dominant model.

Sensitivity analysis was performed by removing one study at a time to assess the stability of these results. After the removal of Wang *et al.* study [25], the resulting heterogeneity across studies decreased from moderate heterogeneity ($\chi 2 = 17.31$; *df*= 8; *p*=0.03; *l*²= 54%) to low ($\chi 2 = 7.14$; *df* = 7; *p*=0.41; *l*²= 2%) in the dominant model (TT *vs.* CC+TC). However, after eliminating the Wang *et al.* study [25], the pooled ORs were not distinctly changed, with stable results. Funnel plots were drawn to determine the risk of bias, and they were symmetric (Figure 5), indicating the absence of publication bias. Finally, STATA software was used to perform Egger's test to calculate publication bias. No publication bias was assessed via Egger's test, which was conducted to provide statistical evidence for funnel plot symmetry (p=0.578 for T *vs*. C; p=0.268 for TT *vs*. CC+TC; p=0.982 for CC *vs*. TC+TT; p=0.253 for TT *vs*. CC; p=0.583 for TC *vs*. CC).

Discussion

During the past few years, some studies have reported the association between HMGB1 polymorphisms (rs2249825, rs1045411, rs1412125 and rs1360485) and different cancer types [25]. After reviewing lots of literatures on HMGB1 polymorphisms, a great deal of literature and information indicate that the HMGB1 rs1045411 polymorphism might be most likely associated with increased cancer risk, though the results are controversial. Hence, a meta-analysis to summarise the inconsistent results from the relevant studies may provide evidence for the correlation between HMGB1 rs1045411 polymorphism and cancer risk. In total, of 3,918 cases and 5,296 controls were included in this study to reveal the correlation between HMGB1 rs1045411 polymorphism and cancer risk. To our knowledge, this meta-analysis represents the largest study of its kind to date. And our results reveal a positive relationship between HMGB1 rs1045411 polymorphism and cancer risk.




Figure 4. Forest plot of rs1045411 in HMGB1 gene and risk of cancer: subgroup analysis by ethnicity using the dominant model.




Figure 5. Funnel plot analysis to detect publication bias. (A) T vs. C. (B) TT vs. CC+TC. (C) CC vs. TC+TT. (D) TT vs. CC. (E) TC vs. CC.

HMGB1 is a tumour-related gene [28], and its overexpression of HMGB1 is associated with the hallmarks of cancer [29], such as unlimited replicative potential, ability to develop blood vessels, evasion of programmed cell death, self-sufficiency in growth signals, insensitivity to inhibitors of growth, inflammation, tissue invasion and metastasis [30]. Because the HMGB1 rs1045411 polymorphism is closely correlated with altered binding of miR-505-5P in the 3'-UTR of mRNA transcripts, HMGB1 gene polymorphisms could emerge as a crucial player in cancer development through a post-transcriptional mechanism [7, 25]. Furthermore, since the rs1045411 polymorphism resides in the 3'-flanking regions, suggesting a role in mRNA stability as miRNAs can bind the 3'-UTR regions of mRNA transcripts and inhibit HMGB1 expression at the post-transcriptional level [25]. Although most studies have demonstrated that HMGB1 is upregulated in nearly all examined tumours, its role might depend on complex

conditions, such as binding partners, diverse locations and different stages [14]. Despite its complexity, the role of HMGB1 in cancer is unquestionable. Thus, further understanding of the mechanisms underlying carcinogenesis is needed to characterize the genetic alterations linked to cancer development. And once the results hold up, HMGB1 SNP rs1045411 might be used as an index of predicting cancer occurrence in the future.

In this study, the significant connection of increased cancer risk and the TT genotype was indicated in the comparisons of TT vs. CC+TC. Though no evidence of association was found between rs1045411 polymorphism and cancer risk in some other genetic models (T vs. C; TC vs. CC; CC vs. TC+TT; TT vs. CC), HMGB1 rs1045411 polymorphism still emerged as a risk factor for cancer. And there were trends towards an association with higher cancer susceptibility, which might become more distinct with a larger sample size. Since the statistically significant differences in cancer risk amongst carriers of this SNP variant compared with non-carriers could not be detected. Whether it was covered up by the counterbalance of its pleiotropic roles in cancer progression or reflected in diversified statistical strategies requires further investigation.

Compared with the former meta-analysis conducted by Kumari T et al. [8], this study have conclusions obtained clear that rs1045411 polymorphism increased cancer risk in some genetic models, especially in the comparison of TT vs. CC+TC while statistical significance was not achieved in any genetic model for all polymorphisms studied by Li XY et al. [7], probably because more studies with larger sample size were included in this meta-analysis and the number of subjects studied was high. Subgroup analysis was also performed by the type of malignancy and ethnicity stratification in the current study, however, no obvious differences were found in the tumour risks in the HMGB1 rs1045411 polymorphism amongst the cancer types except for breast cancer and hepatocellular carcinoma. Hence, more studies are needed for each cancer type. Additionally, though most of the included studies comprised on individuals of Chinese descent except the G. Supic et al. study, in which the subjects were non-Asian, subgroup analysis based on ethnicity was also conducted. But surprisingly, our results demonstrated that rs1045411 polymorphism was positively associated with risks of cancer amongst Hans rather than Caucasians. Therefore, more studies of HMGB1 polymorphism in different ethnic backgrounds, such as, Caucasian, African and others, should be conducted in the future. During the sensitivity analysis, Wang et al. study [25] was found

to contribute to the majority of the heterogeneity in this meta-analysis. After carefully reviewing this study, it was found that the percentages of smokers and alcohol drinkers were much higher in patients than controls, which might be confounding factors, however, after the removal of Wang *et al.* study, the pooled ORs were not distinctly changed, with stable results, which is consistent with previous study [7].

In spite of the considerable efforts to explore the possible relationship between the HMGB1 rs1045411 polymorphism and cancer risk, some limitations of the current meta-analysis should be noted. First, although we tried to gather as much evidence as possible from the present literature, due to the lack of usable data, we could not perform a methodological assessment of certain studies. More studies must be pursued in the future. Second, potential publication bias might arise because several unpublished articles and abstracts were not considered because they were not available. Additionally, due to our language criteria, only studies published in English or Chinese were included; this language restriction might also lead to bias risk and affect the results. Finally, this meta-analysis may have been too underpowered to obtain original data from the included studies.

Despite all the above limitations, by means of investigating associated cases of large samples and analyzing all five genetic models, our study provides new evidence that the HMGB1 rs1045411 polymorphism may be associated with increased cancer risk. However, due to the limitation of heterogeneity and sample size, the results of this study should be interpreted with caution and more work need to be done in the future to validate our findings.

Abbreviations

HMGB1: high-mobility group box protein 1; ORs: odds ratios; Cis: confidence intervals; SNPs: single-nucleotide polymorphisms; HWE: Hardy-Weinberg equilibrium.

Acknowledgements

This work was supported by the Research Foundation of Education Bureau of Yunnan Province, China (Grant No. 2018JS228). And we thank Wangheng Xia and Huoying Chen for assistance in expert technology.

Author Contributions

Juan Xu and Quansong Xia participated in research design; Quansong Xia and Pengzuo Tao participated in the literature research and data analysis; Quansong Xia and Juan Xu participated in the writing of paper.

Competing Interests

The authors have declared that no competing interest exists.

References

- Hu WW, Liu PY, Yang YC, Chen PC, Su CM, Chao CC, et al. Association of HMGB1 Gene Polymorphisms with Lung Cancer Susceptibility and Clinical Aspects. Int J Med Sci. 2017; 14: 1197-1202.
- Torre LA, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
- Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D, et al. Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer. Oncol Rep. 2015; 34: 1779-86.
- Fang X, Yin Z, Li X, Xia L, Quan X, Zhao Y, et al. Multiple functional SNPs in differentially expressed genes modify risk and survival of non-small cell lung cancer in Chinese female non-smokers. Oncotarget. 2017; 8: 18924-18934.
- Shastry BS. SNP alleles in human disease and evolution. J Hum Genet. 2002; 47: 561-6.
- Naykoo NA, et al. Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial growth factor (VEGF) gene with lung carcinoma. Gene. 2017; 608: 95-102.
- Li XY, Liang CH, Yang YJ, Liu L, Du YJ, Liang HS, et al. No association between HMGB1 polymorphisms and cancer risk: evidence from a meta-analysis. Biosci Rep. 2018; 38 (5): BSR20180658.
- Kumari T, Kumar B. High-mobility group box 1 protein (HMGB1) gene polymorphisms and cancer susceptibility: A comprehensive meta-analysis. Clin Chim Acta. 2018; 483: 170-182.
- Xia Q, Xu J, Chen H, Gao Y, Gong F, Hu L, et al. Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review. Onco Targets Ther. 2016; 9: 3917-23.
- Wu XJ, Chen YY, Gong CC, Pei DS. The role of high-mobility group protein box 1 in lung cancer. J Cell Biochem. 2018; 119: 6354-6365.
- Mandke P, Vasquez KM. Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses. DNA Repair (Amst). 2019: 83: 102701.
- Hung SC, Wang SS, Li JR, Chen CS, Yang CK, Chiu KY, et al. Effect of HMGB1 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathological Characteristics. Int J Med Sci. 2018; 15: 1731-1736.
- Chen M, Liu Y, Varley P, Chang Y, He XX, Huang H, et al. High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res. 2015; 75: 1645-56.
- Chung HW, Jang S, Kim H, Lim JB. Combined targeting of high-mobility group box-1 and interleukin-8 to control micrometastasis potential in gastric cancer. Int J Cancer. 2015;137: 1598-609.
- Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Sci Rep. 2016; 6: 29914.
- Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999; 19: 5237-46.
- Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. Mol Aspects Med. 2014; 40: 1-116.
- Polanská E, Dobšáková Z, Dvořáčková M, Fajkus J, Štros M. HMGB1 gene knockout in mouse embryonic fibroblasts results in reduced telomerase activity and telomere dysfunction. Chromosoma. 2012; 121: 419-31.
- Ke S, Zhou F, Yang H, Gong J, Mei Z, Wu L, et al. Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J Oncol. 2015; 46: 1051-8.
- Supic G, Kozomara R, Zeljic K, Stanimirovic D, Magic M, Surbatovic M, et al. HMGB1 genetic polymorphisms in oral squamous cell carcinoma and oral lichen planus patients. Oral Dis. 2015; 21: 536-43.
- Wang B, Yeh CB, Lein MY, Su CM, Yang SF, Liu YF, et al. Effects of HMGB1 Polymorphisms on the Susceptibility and Progression of Hepatocellular Carcinoma. Int J Med Sci. 2016; 13: 304-9.
- Yue L, Zhang Q, He L, Zhang M, Dong J, Zhao D, et al. Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population. J Cell Mol Med. 2016; 20: 1966-73.
- Wu HH, Liu YF, Yang SF, Lin WL, Chen SC, Han CP, et al. Association of single-nucleotide polymorphisms of high-mobility group box 1 with susceptibility and clinicopathological characteristics of uterine cervical neoplasia in Taiwanese women. Tumour Biol. 2016; 37: 15813-15827.
- Wang JX, Yu HL, Bei SS, Cui ZH, Li ZW, Liu ZJ, et al. Association of HMGB1 Gene Polymorphisms with Risk of Colorectal Cancer in a Chinese Population. Med Sci Monit. 2016; 22: 3419-3425.
- Wang D, Qi X, Liu F, Yang C, Jiang W, Wei X, et al. A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk. Oncotarget. 2017; 8: 50109-50116.
- Lin CW, Chou YE, Yeh CM, Yang SF, Chuang CY, Liu YF. A functional variant at the miRNA binding site in HMGB1 gene is associated with risk of oral squamous cell carcinoma. Oncotarget. 2017; 8: 34630-34642.

- Huang BF, Tzeng HE, Chen PC, Wang CQ, Su CM, Wang Y, et al. HMGB1 genetic polymorphisms are biomarkers for the development and progression of breast cancer. Int J Med Sci. 2018; 15: 580-586.
- Martinotti S, Patrone M, Ranzato E. Emerging roles for HMGB1 protein in immunity, inflammation, and cancer. Immunotargets Ther. 2015; 4: 101-9.
- Hanahan D, Weinberg RA, Weinberg. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
- Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi ME. HMGB1 as biomarker and drug target. Pharmacol Res. 2016; 111: 534-544.